MARI.VI
Price:
$19.7
Market Cap:
$35.03M
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name t...[Read more]
Industry
Biotechnology
IPO Date
2019-02-01
Stock Exchange
VIE
Ticker
MARI.VI
According to Marinomed Biotech AG’s latest financial reports and current stock price. The company's current Enterprise Value is 44.26M. This represents a change of 60.90% compared to the average of 27.51M of the last 4 quarters.
The mean historical Enterprise Value of Marinomed Biotech AG over the last ten years is 116.07M. The current 44.26M Enterprise Value has changed 3.71% with respect to the historical average. Over the past ten years (40 quarters), MARI.VI's Enterprise Value was at its highest in in the March 2021 quarter at 215.65M. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.
Average
116.07M
Median
122.28M
Minimum
54.47M
Maximum
178.69M
Discovering the peaks and valleys of Marinomed Biotech AG Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 32.92%
Maximum Annual Enterprise Value = 178.69M
Minimum Annual Increase = -35.81%
Minimum Annual Enterprise Value = 54.47M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 54.47M | -14.27% |
| 2023 | 63.54M | -35.81% |
| 2022 | 98.99M | -29.23% |
| 2021 | 139.87M | -21.72% |
| 2020 | 178.69M | 32.92% |
| 2019 | 134.43M | 5.98% |
| 2018 | 126.84M | 3.38% |
| 2017 | 122.69M | 0.67% |
| 2016 | 121.87M | 2.19% |
The current Enterprise Value of Marinomed Biotech AG (MARI.VI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
72.33M
5-year avg
107.11M
10-year avg
116.07M
Marinomed Biotech AG’s Enterprise Value is
| Company | Enterprise Value | Market cap |
|---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Marinomed Biotech AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Marinomed Biotech AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Marinomed Biotech AG's Enterprise Value?
What is the highest Enterprise Value for Marinomed Biotech AG (MARI.VI)?
What is the 3-year average Enterprise Value for Marinomed Biotech AG (MARI.VI)?
What is the 5-year average Enterprise Value for Marinomed Biotech AG (MARI.VI)?
How does the current Enterprise Value for Marinomed Biotech AG (MARI.VI) compare to its historical average?